Erratum to: Brain Tumor Pathol (2015) 32:22–30 DOI 10.1007/s10014-014-0186-0

In original publication of article, the pyrosequencing assay for IDH2 in Table 1 was incorrectly described as follows:

Sequence to analyze: ANGCAC.

Dispensation order: TATGTCACGCAC.

The correct assay is as follows:

Sequence to analyze: ANGCACGCCCAT.

Dispensation order: GTACTGTCACGC.

The corrected version of Table 1 is given in this erratum.

Table 1 Sequences of the primers for PCR for pyrosequencing, Sanger sequencing, and the pyrosequencing assays
Full size table

In addition, the authors would like to include the below comment with this erratum.

Another point which we would like to comment on is about R172S mutation, an extremely rare mutation in IDH2 for gliomas. Two types of single nucleotide change have been reported as an R172S mutation (c.516G>C and c.516G>T) [1, 2]. In the present study, we validated the assay for IDH2 using a plasmid generated from a clinical case with c.516G>T transition (Fig. 1). Theoretically, the other R172S mutation (c.516G>C) would also be detected by increased peaks at the 6th (G) and 8th (C) dispensations. This type of mutation is extremely rare in gliomas, and our assays are still useful in detecting either mutation.